1.To evaluate the influence of epidural blockade with ropivacaine on the pharmacokinetics of propofol.2.To evaluate the influence of epidural blockade with ropivacaine on the pharmacodynamics of propofol. This includes both the sedative and the…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
patienten die een epiduraal nodig hebben voor een operatie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To evaluate the influence of epidural blockade with ropivacaine on the
pharmacokinetics of propofol.
To evaluate the influence of epidural blockade with ropivacaine on the
pharmacodynamics of propofol. This includes both the sedative and the
hemodynamic effects.
Secondary outcome
hemodynamic parameters
Background summary
Recently, various studies report on the hypnotic sparing effect of central
neuraxis blockade. Local anaesthetics have been shown to enhance sedation and
reduce the hypnotic dose requirements.Up until now, the mechanism and the
magnitude of the sedative sparing effect of central neuraxis blockade remain
unclear.
The pharmacokinetics of intravenous sedatives may be affected by an epidurally
induced change in distribution or clearance of these agents, the
pharmacodynamics of intravenous agents may be affected through the
deafferentation that occurs when central neuraxis blockade is installed.
We propose to study the influence of epidural blockade with ropivacaine on the
pharmacokinetics and pharmacodynamics of propofol when given as intravenous
premedication.
Study objective
1.To evaluate the influence of epidural blockade with ropivacaine on the
pharmacokinetics of propofol.
2.To evaluate the influence of epidural blockade with ropivacaine on the
pharmacodynamics of propofol. This includes both the sedative and the
hemodynamic effects.
Study design
randomized, double-blind, placebo-controlled
Intervention
There are 4 groups of 7 patients. The patients in group 1 will receive no
ropivacaine (10 ml of epidural NaCl 0.9%), the patients in group 2 will receive
50 mg of epidural ropivacaine 7.5 mg/ml, the patients in group 3 will receive
100 mg of epidural ropivacaine 7.5 mg/ml and the patients in group 4 will
receive 150 mg of ropivacaine 7.5 mg/ml.
After the epidural blockade has reached its maximal level. Patients will
receive a target controlled infusion with propofol with an initial target
concentration of 1 µg/ml. After 6, 12 and 18 min this target propofol
concentration will be increased to 2.5 µg/ml, 4 µg/ml and 6 µg/ml. Every 3rd
min, the Ramsay sedation score, the eyelash reflex, the BIS score and state of
consciousness will be tested and an arterial blood sample will be taken for
blood propofol concentration determination. After the loading dose ropivacaine
epidurally we will take according to a predetermined blood sampling schedule
samples to determine the ropivacaine plasma concentrations.
Study burden and risks
The intravenous line is included in the standard anaesthetic care for scheduled
surgical procedures. The arterial will be placed for study purposes. Due to the
venous and/or arterial line some bruising may occur. In this study, duration of
venous line placement will not prolong the normal stay of lines. The arterial
line will be removed directly after termination of the study.
Albinusdreef 2
2333 ZA Leiden
NL
Albinusdreef 2
2333 ZA Leiden
NL
Listed location countries
Age
Inclusion criteria
•ASA class I-II
•Age 18-65 years
•Patients scheduled for surgery requiring epidural anaesthesia and sedation.
Exclusion criteria
•Patients with a BMI >30.
•Participation in a trial on investigational drugs within 3 months prior to the study.
•Known history of hepatic, renal disease or other disease as judged by the investigators.
•Bleeding or coagulation disorders
Patients receiving chronic analgesic therapy.
•Patients using β-blockers
•Pregnancy or lactation.
•Alcohol or drug abuses or history of alcohol/drug abuses.
•Documented or suspected soybean protein and/or drug allergy or amide type local anesthetic allergy
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2010-020050-34-NL |
CCMO | NL32295.058.10 |